Macitentan and morbidity and mortality in pulmonary arterial hypertension
Standard
Macitentan and morbidity and mortality in pulmonary arterial hypertension. / Pulido, Tomás; Adzerikho, Igor; Channick, Richard N; Delcroix, Marion; Galiè, Nazzareno; Ghofrani, Hossein-Ardeschir; Jansa, Pavel; Jing, Zhi-Cheng; Le Brun, Franck-Olivier; Mehta, Sanjay; Mittelholzer, Camilla M; Perchenet, Loïc; Sastry, B K S; Sitbon, Olivier; Souza, Rogério; Torbicki, Adam; Zeng, Xiaofeng; Rubin, Lewis J; Simonneau, Gérald; SERAPHIN Investigators.
In: NEW ENGL J MED, Vol. 369, No. 9, 29.08.2013, p. 809-18.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Macitentan and morbidity and mortality in pulmonary arterial hypertension
AU - Pulido, Tomás
AU - Adzerikho, Igor
AU - Channick, Richard N
AU - Delcroix, Marion
AU - Galiè, Nazzareno
AU - Ghofrani, Hossein-Ardeschir
AU - Jansa, Pavel
AU - Jing, Zhi-Cheng
AU - Le Brun, Franck-Olivier
AU - Mehta, Sanjay
AU - Mittelholzer, Camilla M
AU - Perchenet, Loïc
AU - Sastry, B K S
AU - Sitbon, Olivier
AU - Souza, Rogério
AU - Torbicki, Adam
AU - Zeng, Xiaofeng
AU - Rubin, Lewis J
AU - Simonneau, Gérald
AU - SERAPHIN Investigators
AU - Klose, Hans
PY - 2013/8/29
Y1 - 2013/8/29
N2 - BACKGROUND: Current therapies for pulmonary arterial hypertension have been adopted on the basis of short-term trials with exercise capacity as the primary end point. We assessed the efficacy of macitentan, a new dual endothelin-receptor antagonist, using a primary end point of morbidity and mortality in a long-term trial.METHODS: We randomly assigned patients with symptomatic pulmonary arterial hypertension to receive placebo once daily, macitentan at a once-daily dose of 3 mg, or macitentan at a once-daily dose of 10 mg. Stable use of oral or inhaled therapy for pulmonary arterial hypertension, other than endothelin-receptor antagonists, was allowed at study entry. The primary end point was the time from the initiation of treatment to the first occurrence of a composite end point of death, atrial septostomy, lung transplantation, initiation of treatment with intravenous or subcutaneous prostanoids, or worsening of pulmonary arterial hypertension.RESULTS: A total of 250 patients were randomly assigned to placebo, 250 to the 3-mg macitentan dose, and 242 to the 10-mg macitentan dose. The primary end point occurred in 46.4%, 38.0%, and 31.4% of the patients in these groups, respectively. The hazard ratio for the 3-mg macitentan dose as compared with placebo was 0.70 (97.5% confidence interval [CI], 0.52 to 0.96; P=0.01), and the hazard ratio for the 10-mg macitentan dose as compared with placebo was 0.55 (97.5% CI, 0.39 to 0.76; P<0.001). Worsening of pulmonary arterial hypertension was the most frequent primary end-point event. The effect of macitentan on this end point was observed regardless of whether the patient was receiving therapy for pulmonary arterial hypertension at baseline. Adverse events more frequently associated with macitentan than with placebo were headache, nasopharyngitis, and anemia.CONCLUSIONS: Macitentan significantly reduced morbidity and mortality among patients with pulmonary arterial hypertension in this event-driven study. (Funded by Actelion Pharmaceuticals; SERAPHIN ClinicalTrials.gov number, NCT00660179.).
AB - BACKGROUND: Current therapies for pulmonary arterial hypertension have been adopted on the basis of short-term trials with exercise capacity as the primary end point. We assessed the efficacy of macitentan, a new dual endothelin-receptor antagonist, using a primary end point of morbidity and mortality in a long-term trial.METHODS: We randomly assigned patients with symptomatic pulmonary arterial hypertension to receive placebo once daily, macitentan at a once-daily dose of 3 mg, or macitentan at a once-daily dose of 10 mg. Stable use of oral or inhaled therapy for pulmonary arterial hypertension, other than endothelin-receptor antagonists, was allowed at study entry. The primary end point was the time from the initiation of treatment to the first occurrence of a composite end point of death, atrial septostomy, lung transplantation, initiation of treatment with intravenous or subcutaneous prostanoids, or worsening of pulmonary arterial hypertension.RESULTS: A total of 250 patients were randomly assigned to placebo, 250 to the 3-mg macitentan dose, and 242 to the 10-mg macitentan dose. The primary end point occurred in 46.4%, 38.0%, and 31.4% of the patients in these groups, respectively. The hazard ratio for the 3-mg macitentan dose as compared with placebo was 0.70 (97.5% confidence interval [CI], 0.52 to 0.96; P=0.01), and the hazard ratio for the 10-mg macitentan dose as compared with placebo was 0.55 (97.5% CI, 0.39 to 0.76; P<0.001). Worsening of pulmonary arterial hypertension was the most frequent primary end-point event. The effect of macitentan on this end point was observed regardless of whether the patient was receiving therapy for pulmonary arterial hypertension at baseline. Adverse events more frequently associated with macitentan than with placebo were headache, nasopharyngitis, and anemia.CONCLUSIONS: Macitentan significantly reduced morbidity and mortality among patients with pulmonary arterial hypertension in this event-driven study. (Funded by Actelion Pharmaceuticals; SERAPHIN ClinicalTrials.gov number, NCT00660179.).
KW - Adult
KW - Double-Blind Method
KW - Exercise Tolerance
KW - Female
KW - Hospitalization
KW - Humans
KW - Hypertension, Pulmonary
KW - Kaplan-Meier Estimate
KW - Male
KW - Middle Aged
KW - Pyrimidines
KW - Receptor, Endothelin A
KW - Receptor, Endothelin B
KW - Sulfonamides
U2 - 10.1056/NEJMoa1213917
DO - 10.1056/NEJMoa1213917
M3 - SCORING: Journal article
C2 - 23984728
VL - 369
SP - 809
EP - 818
JO - NEW ENGL J MED
JF - NEW ENGL J MED
SN - 0028-4793
IS - 9
ER -